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1006-179 Elution of Everolimus and Sirolimus From a 
Biodearadable Polvmer Coated Stent Inhibits 
Neointimal Hyperplasia Without Inflammation or 
Toxicity 
Saibal Kar Taku Honda, Dougal Mcclean, Kanama Takizawa, Michael Fishbein, -I 
Hidehiko Honda, John Shulza, Neal Eigler, Frank Litvack, Cedars-Sinai Medical Center, 
Los Angeles, CA, UCLA Medical Center, Los Angeles, CA 
Background: Earfy clinical trials with drug eluting stents have suggested limitations 
including edge restenosis and malaposition. Persistent bio-stable polymer and/or drug 
may be causal. Biodegradable polymers hold potential advantage if they are metabolized 
prior to tissue toxicity and deliver drug during the optimal window. Local delivery of active 
drug from a slowly biodegradable, high molecular weight polylactic acid (PLA) coated 
stent could lead to inhibition of intimal hyperplasia without impaired healing. 
Methods: We compared PLA polymer containing 160 or 220 ug of Everolimus(E), 180 ug 
Sirolimus(S), and bare metal stent. 40 stents were deployed in coronary artehes of 19 
pigs with sacrifice at 28 days. Endpoints were assessed by quantitative coronary angiog 
raphy @CA), histomorphometry, and histology at 28 and 90 days. 
Results:There was reduction of intimal hyperplasia as assessed by QCA and histomor- 
phometry by both E and S (Table 1). At both 28 and 90 days, there was complete re- 
endothelialization and ho difference in inflammation or fibrin between the bare stent and 
druglpolymer groups. 
Conclusion: Everolimus and Sirolimus delivered via stent and thin layer biodegradable 
polymer are equally effective at inhibition of intimal hyperplasia. At follow-up evaluation. 
complete healing without toxic or inflammatory reaction was seen. A clinical trial to deter- 
mine safety and efficacy of the Everolimus coated stent has commenced. 
Table 1. QCA and Histomorphometric parameters at 28 days 
Bare(S) Low E(17) High(E) S(5) 
Late Loss Index 
Area Stenosis% 
lntimal Area 
Injury Score 
0.44*0.20 0.28*0.14 0.29*0.10T 0.3kO.12 
64+24t 4lil2 38ill$ 33*13t 
5.2*1.7 2.8+0.6$ 3.0*1 .o* 2.4*1 .O$ 
1.5*0.9 1.550.5 t .5*0.5 1.6iO.5 
$ p < 0.001 T pco.01 
1006-l 80 Reducing Neointimal Proliferation by a Stent-Based 
Delivery of Nitric Oxide in a Porcine Carotid Overstretch 
Injury Model 
Donamina Hou Hugh Narciso, Kirti Kamdar, Yiyu Zhao. William R. Henog, Bruce 
Barclay, Keith L. March, ICVBM, Indianapolis, IN, Vascular Architects, Inc, San Jose, CA 
Background: Nitric oxide (NO) is a potent vasodilator and anti-platelet agent that sup- 
presses vascular smooth muscle cell proliferation. We hypothesized that releasing NO 
from a stent would reduce neointimal hyperplasia after vascular intervention without 
affecting systemic hemodynamics. The present study was designed to test the efficacy of 
ah NO eluting stent in a porcine carotid overstretch injury model. 
Methods and Results: ePTFE-covered stents (aSpireS Vascular Architects, Inc) with 
the NO-releasing compound sodium nitroprusside (SNP. NO donor)/silicone mixture con- 
taining 54.5 pg SNP were tested. In Virro measurable levels of NO were detected and 
released for 87 days in a conttnuous flow closed-loop PVC tubing system containing PBS 
with a flow rate of 1OOmllmin at room temperature. Six SNPIsilicone mixture coated 
ePTFE-covered stents and six uncoated aspire stents (without SNPlsilicone mixture) 
were implanted in the carotid arteries of 6 pigs following balloon overstretch injury with a 
balloon artery ratio of 1.3:l. Pigs were terminated at 28 days and the vessels were har- 
vested. Quantitative angiography analysis documented ho differences between the base- 
tine vessel parameters. At sacrifice, stents coated with NO significantly decreased 
angiographic lumen narrowing from 37% (control) to 28% (NO eluting, p = 0.022). No 
drug toxicity was observed. Morphometric measurements indicated that the injury score 
was equivalent between groups. The mean intimal thickness was significantly lass in NO 
eluting stent vessels than controls (0.12+0.05 mm vs. 0.43iO.09 mm; P = 0.008). The 
mean neointimal area was also markedly reduced (0.49&0.16 mmz) for arteries receiving 
NO eluting stents compared with the controls (2.40*0.39 mm* , P = 0.00983). Factor VIII 
staining demonstrated complete vessel reendothelialization in most segments of vessel 
of both groups. Conclusions: ePTFE-covered aspire stent-based sustained delivery of 
NO donor via SNPlsilicone mixture is feasible and effectively reduces in-stent neointimal 
hyperplasia at 28 days in a porcine carotid overstretch model. Long-term follow-up is 
needed to determine the persistence of this effect oh neointimal suppression. 
1006-181 Stents Coated With the Lipophilic Compound A24 
Profoundly Inhibit Neointimal Formation in the Porcine 
Coronary Model 
Andrew J. Carter, Lisa Welch, Lori Gibson, Souad Sedlik, Renu Virmani, Providence 
Heart Institute, Portland, OR, Armed Forces Institute of Pathology, Washington, DC 
Background: Stent-based immunosuppressive therapy reduces restenosis by impairing 
vascular smooth muscle cell proliferation and mitigating the inflammatory response to the 
prosthesis. 
Methods: We evaluated the feasibility and efficacy of A24 eluting stems in a porcine cor- 
onary model. Stainless steel balloon expandable stents were coated with a non-erodable 
pOlym.3 or pOlymi?r with A24 (10 w/mm). Fifteen pigs underwent placement of oversized 
bare metal (n = 15) polymer (n = 8) and A24 (n = 9) stents in the coronary arteries. 
Results: At 28-days. histology demonstrated similar mean injury scores for the control, 
polymer and A24 coated stents. The mean neointimal area (mm*) was significantly 
reduced for A24 (1.70 f 0.47) as compared with polymer (2.82 f 1.24) and control (2.89 
f 1.91) stents (p c 0.005). The 40% reduction in neointimal area resulted in significantly 
less mean percent diameter stenosis for A24 (19.4 f 4.0 %) as compared with polymer 
(30.3 * 12.1 %), and control (29.4 * 15.5 %) stents (p < 0.001). Twelve of the 45 bare 
metal stent cross sections exhibited a giant cell reaction while none of the 26 sections 
from the A24 stems had a giant cell response. 
Concfusions: Stent-based delivery of A24 inhibits neointimal formation and the inflam- 
matory response to the prosthesis in the porcine coronary model. Further study IS neces- 
sary to determine the dose-response and long-term effects A24 eluting stents in the 
porcine coronary model. 
1006-l 82 First-in-Human Study of Angiopeptin-Eluting Stents: A 
Quantitative Coronary Angiography and Volumetric 
Intravascular Ultrasound Study 
On-Hina Kwok Wing-Hing Chow, Chi-Hang Lee, William Ng. Tin-Chu Law, Alex Chiu, 
Jeffrey J. Popma. Grantham Hospital, Hong Kong, Hong Kong, Brigham and Women’s 
Hospital, Boston. MA 
Background: Angiopeptin. a somatostatin analogue, has been shown to reduce neointi- 
mal hyperplasia after stenting in various animal models. Angiopeptin inhibits smooth 
muscla cell proliferation through attenuating the production and release of several growth 
factors including PDGF. b-FGF, IGF-1 and EGF. BiodivYsio DD Phosphorylcholine (PC) 
coated stent provides a viable platform for local delivery of anti-proliferative agents to the 
coronary artery. Oblective: To evaluate the feasibility, safety and impact oh tissue growth 
of Angiopeptin-eluting BiodivYsio DD PC stems in human native de nova coronary 
lesions. Method: 13 patients (14 lesions) underwent intravascular ultrasound(lVUS)- 
guided Angiopeptin-eluting stents implantation. The mean age was 83.7+8.7 yrs. 46.2% 
of the patients were diabetic. The clinical follow up period was 28.9+6.8 weeks. Coronary 
arteries between 3.0 and 4.0mm in diameter and lesion lengthcl8mm were included. 
Results: Lesion locations were 9 LAD, 3 LCx and 2 RCA. 13 stents were loaded with 22 
microgram of Angiopeptin and one with 126 microgram. No major adverse cardiac 
events had occurred. Off-line quantitative coronary analysis(QCA) showed pre-proce- 
dural mean reference diameter of 3.23r0.72mm. Minimal luminal diameter(MLD) 
improved from 0.69*0.29mm to 3.19+0.60mm. Mean lesion length,was 12.38~2.04mm. 
8 consecutive patients (9 stents with 22 microgram Angiopeptin) underwent 6-month 
angiographic and volumetric IVUS follow-up. Late loss was 0.55i0.36mm and late loss 
index was 0.23*0.13 by QCA. Binary restenosis was 0%. Follow-up stent volume by 
IVUS was 199.6~123.lmmJ and percentage neointimal hyperplasia volume was 
20.7+28.5%. There was ho edge effect and late stent mal-apposition. Conclusion: Angio- 
peptin-eluting BiodivYsio DD PC stent appears to be feasible and safe in treating native 
de nova coronary lesions. Low-dose (22 microgram) Angiopeptin-eluting stents resulted 
in modest degree of neointimal hyperplasia and zero binary restenosis. More patients will 
be enrolled in the trial with escalating doses of Angiopeptin and the encouraging prelimi- 
nary results warrant further confirmation by randomized controlled trial. 
1006-l 83 First Human Experience Using a New Everolimus Stent 
Coating: Procedural and Six-Month Follow-Up Results 
of the FUTURE Trial 
Eberhard Grube, Lutz Buellesfeld, Ralf Mueller, Manfred Staberock. Guide Selbach. 
Thomas Schmidt, Ulrich Gerckens, Heart Center Siegburg, Siegburg, Germany 
Background: Sirolimus and Paclitaxel eluting stents have shown significant reduction of 
restenosis after stent implantation with remarkable improvement of patient outcome. 
Everolimus is a new anti-proliferative agent binding to cytosolic immunophyllin FKBP12 
and inhibiting arowth factor-driven cell oroliferation with oromisina results in animal stud- _- _ 
ies demonstrating a 50% reduction of neointimal proliferation compared with a bare 
metal stem. The FUTURE trial has been conducted to evaluate both safetv and efficacv 
of the new ChallengeStent, which is coated by a bio-erodable polymer carrying the 
agent Everolimus. 
Methods: The FUTURE trial, which has started in May 2002, is a prospective, random- 
ized, single blinded study including a clinical follow-up at 30 days and 12 months post 
procedure and a 6 month angiographic and IVUS follow-up, to evaluate acute gain and 
late lumen loss due to neointimal proliferation. The primary endpoint is MACE at 30-days. 
The secondary endpoint is to compare the clinical performance of the Everotimus coated 
stent (Challenge-Stem) as compared to the control bare metal S-Stent with regards to 
device success, MACE and restenosis rate at 6.months follow-up. In this randomized 
unbalanced 2:1 ratio, 24 and 12 patients are allocated to the drug and control groups 
respectively. De hove coronary lesions with a reference diameter between 2.75-4.0mm 
and lesion length cl8mm were enrolled with mandatory predilatation. 
Results: To date, the patient enrollment has been completed including 36 patients with a 
procedural success rate of 100%. No in-hospital MACE were reported. At 30.day clinical 
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follow-up, all patients in each study arm remained free of any cardiac events. There were 
no target lesion revascularisatkms reported so far. 6 month follow-up aXaminatiOnS are 
expected to stalt in September 2002. At time of presentation, we will present the com- 
plete 6 month follow-up angiographic and IVUS data. 
Conclusions: The FUTURE trial represents a pioneer experience demonstrating Safety of 
the new Everolimus coated Challenge-Stent with a 100% procedural success rate and an 
uneventful in-hospital and m-day follow-up in all patients. The 6 month follow-up data will 
be presented. 
1006-184 Evaluation of a Tacrolimus-Eluting Coronary Stent With 
Nanoporous Ceramic Coating in Treatment of Native 
Coronary Artery Lesions: Phase I and II of the PRESENT 
Study 
Ulrich Gerckens. Lutz Buellesfeld. Dieter Horstkotte. Ralf Mueller, Manfred Staberock, 
Guide Selbach. Thomas Schmidt, Eberhard Grube. Healt Center Siegburg, Siegburg, 
Germany, Heart Center Bad Oeynhausen. Bad Oeynhausen, Germany 
Background: Drug eluting stents (DES)has recently emerged as one of the most promis- 
Ing techniques for intetventional treatment of coronary lesions. Tacrolimus is an antipro- 
liferative and antiinflammatory agent with proven efficacy in other therapeutical areas 
(transplant medication). The antiproliferative effect in coronary applications is selectively 
focused on smooth muscle cell activities rathsr than inhibition of endothelial cell prolifera- 
tion. To evaluate both safety and feasibility of a Tacrolimus eluting stent, which utilizes a 
nanoporous aluminium oxide ceramic as drug carrier, the PRESENT study have been 
conducted.Methods and Results: The PRESENT Study is a prospective study, evaluat- 
ing the ceramic coated coronary stent with and without Tacrolimus in treatment of native 
coronary de-nova lesions with 30 patients in each arm. Primary endpoint was 30-day 
safety defined as absence of MACE. Angiographic and IVUS follow-up was scheduled at 
6 months after index procedure. The interim analysis after enrollment of 22 and 2 
patients with DES and contol stent implantation, respectively, showed absence of in-hos- 
pital and 30.day MACE in each group; however, 3 target vessel revascularisations 
beyond the 30 day period in the group of DES were observed and the trial was halted 
(phase I). After modification of the stent design with increase in drug dosages loaded on 
the DES, the trial was restarted evaluating the bare ceramic coated stent and the modi- 
fied high dose drug eluting stent in 30 patients each (phase II). To date, 24 patients in the 
high dose DES group has been enrolled without any adverse cardiac events after DES 
implantation. At time of presentation, complete procedural and 30 day follow-up data of 
the phase I and II patient population as well as B-month angiographic and IVUS data will 
be presented. 
Conclusion: The PRESENT trial demonstrates safety and feasibility of a new ceramic 
coated coronary stent with and without elution of Tacrolimus. The need of target vessel 
revascularisations in the low dose group (phase I) might suggest an inappropriate drug 
loading of the first stem version. Phase II with high dose Tacrolimus will clarify the effi- 
cacy of this concept in treatment of coronary lesions. 
1006-185 Evaluation of the BiodivYsio Stent With Matrix HI 
Coating Designed for Local Drug Delivery in Coronary 
Arteries: A Randomized Trial 
Helmut SchOhler$ Adnan Kastrati, Julinda Mehilli, J&g Hausleiter, Jiirgen Pache, Josef 
Dirschinger, Albert Schbmig. Deutsches Herzzentrum. Munich, Germany, 1. Med. Klinik 
rechts der Isar. Munich, Germany 
Background: Stent coating integrating an active drug for local delivery is currently 
Intensely investigated to prevent restenosis after coronary stent placement. Stem design, 
surface, and as shown in the ISAR-STEREO l&2 trials, strut thickness have a significant 
impact on restenosis. The commercially available BiodivYsio stent is a thin-strut stent 
(9Opm) with a phosphorylcholine coating (PC) with favorable long-term results as shown 
by the SOPHOS trial. The standard PC coating has been modified to allow local delivery 
of biomolecules (batimastat. angiopeptin and others). Goal of the present study was to 
evaluate the efficacy of the BiodivYsiostent with this Matrix HI polymer coating (MBIO) 
without an active drug, by comparison with the Guidant RX MultiLink (ML) which was the 
stent with the lowest restenosis rate in both ISAR-STEREO trials. 
Methods & Results: Patients with symptomatic coronary artery disease (acute coronary 
syndrome in 36.7%) were randomly asslgned to either the MBIO (n=142) or the ML 
(n=l42). Baseline clinical and angiographic characteristics did not differ significantly 
between the 2 groups; vessel size was 3.OOi.54 (MBIO) vs. 3.06+.50mm (ML), lesion 
length 13.2+6.9 vs. 13.1&.9mm. Number of stents implanted (1.3k.9 vs. 1.3+.6), bal- 
loon/vessel ratio (1.16+.12 vs. 1.16~.13), and final %-diameter stenosis (5.629.7 vs. 
5.OA6.9) did not differ significantly. Repeat angiography (performed in 60% of eligible 
pts.) revealed restenosis (~50% diameter stenosis) in 37.3% with MBIO and 17.3% with 
ML (pc.OOl), late loss was 1.17*.75 vs 0.98+.63mm (p=.O4). After 1 year, target vessel 
revascularization was done in 22.5 vs. 13.4% (pz.04). the rate of death or myocardial inf- 
arction was not signiftcantly different (4.9 vs. 4.9%). 
Conclusions: In this randomized comparison, the BiodivYsiostent with Matrix HI poly- 
mer coating (without active drug) has less favorable results. As the restenosis rate for the 
standard PC-coated BiodivYsio was much lower in the SOPHOS trial (17.7%). these 
data suggest a negative effect of the Matrix HI polymer coating. This needs to be 
accounted for when designing and interpreting studies with this stem coating. 
1006-l 86 Titanium Nitride-Oxide Coated Stent: Six-Month 
Angiographic and Intravascular Ultrasound Follow-Up 
Christophe Caussin Marie-Jeanne Alibelli, Meyer Elbaz, Martial Hamon, Gilles Grollier, 
Philippe Commeau, Bernard Lancelin, C.C. Marie Lannelongue. Le Plessis Robinson, 
France 
Titanium nitride oxyde (Ti-NO) is biologically inert has an excellent biocompatibility 
exemplified by the lack of a redox and hydrolysis reaction as well as an absent complex 
metal ion-organic molecule binding formation. Ti-NO coated stent has significantly 
reduced neointimal proliferation compared to stainless steel stent in pigs. The aim of our 
study was to prospectively evaluate the feasibility and safety of a Ti-NO stainless steel 
coated stem (Helistent @, Hexacath, France) in humans. 
Inclusion criteria were a single lesion less than15 mm in length in a native coronary artery 
with a reference diameter between 3.0 and 4.0 mm eligible for PCI. Exclusion criteria 
were high-grade calcifications, ostial or bifurcation lesion, less than 72 hours acute myo- 
cardial infarction. Clinical follow-up was performed at one month and angiographic fol- 
low-up was systematically performed at six months. QCA and IVUS analysis were 
centralized. 
133 patients were included in the study. 40 pts were selected for post implantation and 
six months IVUS analysis. Mean age was 62.4 * 11.4 y. Prior history of diabetes was 
19%. CABG :I%, PCI: 5%. MI 19%. Clinical presentation was unstable angina : 43%, 
stable angina: 23%. post Ml : 17%, silent ischemia: 17%. ACC/AHA classification lesion 
was A:29%, B: 71%. Reference diameter with QCA analysis was 3.21* 0.36mm. MLD 
pre and post stent were I.142 0.32 and 2.99+ 0.35mm. Post implantation IVUS reference 
diameter was 4.32+/- 0.45mm, reference area was 14.61+/-2.57mm2, stent symetry was 
0.9+/-0.03 and stent lumen cross section area was 9.01+/-2.05mm2. Success rate 
implantahon was 100%. In hospital events was one death due to per-procedure aortic 
dissection, one regressive stroke and two groin haematomas. At one month no subacute 
thrombosis, no TLR and no Ml was observed. 
In conclusion immediate and one month follow-up results are very promising. Six months 
angiographic and IVUS follow-up is ongoing, complete results will be communicated dur- 
ing the presentation. 
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1007-l 73 Incidence of Renal Artery Stenosis in 2,111 Patients 
Undergoing Coronary Angiography: A Model of 
Predictive Risk of Renal Artery Stenosis 
Grayson G. Geary,David J. Tanous David L. Ross, Westmead Hospital, Sydney, 
Australia 
Background: Renal artery stenosis (RAS) is an important cause of hypertension and 
ischemic renal disease and should be identified in patients (pts) where possible. Data on 
the predictive risk of RAS at the time of coronary angiography for different patient profiles 
is lacking. Our aim was to determine the incidence of RAS in a large group of pts under- 
going coronary angiography and to develop a model to determine the risk of RAS for any 
subgroup of pts. Methods: A total of 2111 consecutive pts were screened for RAS with a 
contrast injection in the descending aorta after the ventriculogram. Multiple risk factors 
were assessed. Results: RAS was present in 1% of pts without CAD and in 13% of pts 
with CAD. Independent risk factors for RAS in pts with CAD were age (Odds ratio (OR) 
l.O5/year, p<O.OOl), female sex (OR 1.91, p<O.OOl), peripheral vascular disease (PVD) 
(OR 2.32, p<O.OOl), cerebrovascular disease (CVD) (OR 1.60, p&05), 3 vessel disease 
(OR 3.14. p<O.OOl) and hypertension (OR 1.56, p=O.Ol). A model was developed utlliz- 
ing these risk factors which enables the prediction of RAS in different patient profiles. An 
example is shown for males aged 60 with hypertension and CAD. Conclusions: RAS was 
rare in pts without CAD. In pts with CAD, there was a relatively high Incidence of unsus- 
pected RAS (13%). In pts with CAD and RAS there was a high incidence of other vascu- 
lar disease. The incidence of RAS in pts with CAD can be predicted using the model 
developed and may aid in determining which pts should be screened. 
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